TY - JOUR
T1 - Arsenic exposure and cardiovascular disease
T2 - An updated systematic review
AU - Moon, Katherine
AU - Guallar, Eliseo
AU - Navas-Acien, Ana
PY - 2012/12
Y1 - 2012/12
N2 - In epidemiologic studies, high-chronic arsenic exposure has been associated with cardiovascular disease, despite methodological limitations. At low-moderate arsenic levels, the evidence was inconclusive. Here, we update a previous systematic review (Am J Epidemiol 2005;162:1037-49) examining the association between arsenic exposure and cardiovascular disease. Eighteen studies published since 2005 were combined with 13 studies from the previous review. We calculated pooled relative risks by comparing the highest versus the lowest exposure category across studies. For high exposure (arsenic in drinking water>50 μg/L), the pooled relative risks (95 % confidence interval) for cardiovascular disease, coronary heart disease, stroke, and peripheral arterial disease were 1.32 (95 % CI:1.05-1.67), 1.89 (95 % CI:1.33-2.69), 1.08 (95 % CI:0.98-1.19), and 2.17 (95 % CI:1.47-3.20), respectively. At low-moderate arsenic levels, the evidence was inconclusive. Our review strengthens the evidence for a causal association between highchronic arsenic exposure and clinical cardiovascular endpoints. Additional high quality studies are needed at low-moderate arsenic levels.
AB - In epidemiologic studies, high-chronic arsenic exposure has been associated with cardiovascular disease, despite methodological limitations. At low-moderate arsenic levels, the evidence was inconclusive. Here, we update a previous systematic review (Am J Epidemiol 2005;162:1037-49) examining the association between arsenic exposure and cardiovascular disease. Eighteen studies published since 2005 were combined with 13 studies from the previous review. We calculated pooled relative risks by comparing the highest versus the lowest exposure category across studies. For high exposure (arsenic in drinking water>50 μg/L), the pooled relative risks (95 % confidence interval) for cardiovascular disease, coronary heart disease, stroke, and peripheral arterial disease were 1.32 (95 % CI:1.05-1.67), 1.89 (95 % CI:1.33-2.69), 1.08 (95 % CI:0.98-1.19), and 2.17 (95 % CI:1.47-3.20), respectively. At low-moderate arsenic levels, the evidence was inconclusive. Our review strengthens the evidence for a causal association between highchronic arsenic exposure and clinical cardiovascular endpoints. Additional high quality studies are needed at low-moderate arsenic levels.
KW - Arsenic
KW - Cardiovascular disease
KW - Meta-analysis
KW - Systematic review
UR - http://www.scopus.com/inward/record.url?scp=84870521565&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84870521565&partnerID=8YFLogxK
U2 - 10.1007/s11883-012-0280-x
DO - 10.1007/s11883-012-0280-x
M3 - Review article
C2 - 22968315
AN - SCOPUS:84870521565
SN - 1523-3804
VL - 14
SP - 542
EP - 555
JO - Current atherosclerosis reports
JF - Current atherosclerosis reports
IS - 6
ER -